In particular, a high TG2 expression is correlated with a poorer survival rate in LUSC (Lung squamous cell carcinoma) (p = 0.002) (Fig. 1b), GBM (Glioblastoma multiforme) (p = 0.0027) (Fig. 1c), KIRC (Kidney renal clear cell carcinoma) (p = 0.029) (Fig. 1d), and LGG (Brain Lower Grade Glioma) (p = 0.0035) (Fig. 1e). Here, TGM2 is linked to central nervous system cancer.